<?xml version="1.0" encoding="UTF-8"?>
<p>The widespread adoption of intensive therapy and the subsequent introduction of novel agents in the treatment of multiple myeloma (MM) inevitably raises questions as to effects on health‐related quality of life (HR‐QoL). However, there is still relatively little published quality of life (QoL) data in systematically treated and assessed patients, notably in the first‐line treatment setting.</p>
